Hydrogenology
Hydrogenology editorial study record

Inhaled hydrogen ameliorates endotoxin‐induced bowel dysfunction

Sakata H, Okamoto A, Aoyama-Ishikawa M, Yamashita H, Kohama K, Fujisaki N, Yamada T, Kotani J, Tsukahara K, Iida A, Nakao A. · 2017.

PreclinicalInhaled H₂Published 2017
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Preclinical

Reported design

Controlled endotoxin animal and cell study

Research topic

Gastrointestinal health

Administration classification

Inhaled H₂

Study result signal

Positive preclinical signal.

Outcome type

Animal gastrointestinal-function and mechanistic outcomes.

Reported in the source

Methods at a glance

Population or model

Rodents with endotoxin-associated bowel dysfunction and related cell assays.

Sample

Small animal and cell groups with assay-specific counts.

Duration

Acute post-endotoxin protocol.

Intervention

1.3% inhaled hydrogen after endotoxin exposure.

Hydrogen form

Inhaled molecular H₂.

H₂ specification

1.3% H₂ in the reported carrier mixture.

H₂ flow

Absolute H₂ flow was not reported separately.

O₂ delivered with H₂

Carrier-gas composition was reported; no Brown's-gas classification is inferred.

Comparator

Endotoxin injury without hydrogen and laboratory controls.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Gastrointestinal transit, barrier function, inflammation and related signaling.

Reported result

Hydrogen was reported to improve gastrointestinal transit and several barrier or inflammatory measures after endotoxin exposure.

Results-extraction completeness

The full article was checked for methods, intervention details, outcomes, positive and null findings, funding and conflicts. This record does not imply medical efficacy.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Preclinical evidence only; multiple mechanistic endpoints and small groups.

Applies directly to

The reported endotoxin bowel-dysfunction models only.

Preliminary appraisal framework

SYRCLE animal-study tool — preliminary

Preliminary risk-of-bias status

Some concerns

Appraisal rationale

Controls were present, but sequence generation, concealment and blinded assessment were incompletely reported.

Appraisal domains

Sequence generation checked where reported · Allocation concealment generally unclear · Personnel blinding generally unclear · Outcome-assessor blinding generally unclear · No prospectively registered analysis plan identified

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 29123834 · DOI: 10.1002/ams2.218

Publisher access

A free full article is available through PubMed Central.

Extraction basis

Official PubMed Central full article and PubMed bibliographic record; source identity, methods, intervention, results, funding and conflicts checked 10 August 2026.

Record revision

2026-08-10